About TheraSphere

Unique, optimal design for tumor control

The only Y-90 microsphere with radiation embedded throughout
Maximizes radiation per microsphere (RPM) while minimizing risk of stasis or reflux
Arrives in a personalized, sealed source vial with easy and safe set-up
Dose vial administration takes less than five minutes

See how TheraSphere is made

Precision-manufactured glass microspheres are the most powerful radiation therapy on the market.

Discover more TheraSphere product information

Safety and efficacy

TheraSphere is an efficient and powerful HCC therapy with a good patient safety profile and proven, durable outcomes. TheraSphere’s unique ability to safely deliver high-dose radiation with fewer spheres allows for maximum absorbed dose and increased tumor response while preserving healthy tissue.¹ TheraSphere is also the only FDA-approved Y-90 treatment for HCC.

Targeted for control

TheraSphere is uniquely engineered to have unmatched radiation per microsphere (RPM) to maximize repetitive and cumulative radiation exposure to tumor cells. This allows you to confidently destroy tumor cells with proven ablative dosing and helps drive complete pathological necrosis (CPN). And, the flexibility of personalized doses serves your treatment intent — whether curative or palliative.

Product details

TheraSphere Y-90 glass microspheres are precisely formulated with high-dose Y-90, delivered with targeted accuracy into hepatocellular carcinoma (HCC) tumors to improve tumor* response and provide longer overall patient survival. ^2,3

Pure beta emitter
Average energy of 0.9367 MeV
Average tissue penetration range of 2.5 mm

Powerful interventional radiotherapy

Available personalized doses: 3 – 20 GBq (in 0.5 GBq increments), ranging from 750,000 to 5 million microspheres
Insoluble glass microspheres with a mean diameter of 20-30 µm
Y-90 is an integral constituent of the glass

Part of a holistic HCC treatment plan

Early treatment with TheraSphere allows multidisciplinary teams to maximize the probability of positive tumor response. In combination with other therapies, TheraSphere widens the field of treatment possibilities – to ultimately improve patient outcomes.

See Referring physician information

Reimbursement

Find coding and economic resources for health care practitioners and their partners.

See reimbursement resources

Have your questions answered

Receive additional information to help determine if TheraSphere could be a treatment option for your patients.

References

Lam, M., Garin, E., Maccauro, M. et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging (2022). https://doi.org/10.1007/s00259-022-05774-0.
LEGACY: Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study. Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819. Percentage shown reflects patients who were eligible for tumor response assessment.
Garin E, Tselikas L, Guiu B et al. Personalized versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021, 6: 17-29.

*Refers to HCC or associated tumors 

TheraSphere indications, safety, and warnings

TheraSphere is a registered trademark of Theragenics Corporation used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation.